Medical Hypotheses
Volume 68, Issue 5 , Pages 979-987, 2007

Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders

  • James Jeffrey Bradstreet

      Affiliations

    • International Child Development Resource Center, Melbourne and Florida Hospital, Celebration, 1688 West Hibiscus Boulevard, Melbourne, FL 32901, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 321 953 0278.
  • ,
  • Scott Smith

      Affiliations

    • International Child Development Resource Center, Melbourne and Florida Hospital, Celebration, 1688 West Hibiscus Boulevard, Melbourne, FL 32901, United States
  • ,
  • Doreen Granpeesheh

      Affiliations

    • Center for Autism Related Disorders, Tarzana, CA, United States
  • ,
  • Jane M. El-Dahr

      Affiliations

    • Tulane University Health Sciences Center, Departments of Pediatrics and Medicine, Section of Pediatric Allergy, Immunology and Rheumatology, New Orleans, LA, United States
  • ,
  • Daniel Rossignol

      Affiliations

    • University of Virginia, Department of Family Medicine, P.O. Box 800729, Charlottesville, VA, United States

Received 2 October 2006; accepted 5 October 2006. published online 08 December 2006.

Summary 

Multiple studies now demonstrate that autism is medically characterized, in part, by immune system dysregulation, including evidence of neuroglial activation and gastrointestinal inflammation. This neuroglial process has further been characterized as neuroinflammation. In addition, a subset of autistic children exhibit higher than average levels of androgens. Spironolactone is an aldosterone antagonist and potassium-sparing diuretic with a desirable safety profile. It possesses potent anti-inflammatory and immune modifying properties that might make it an excellent medical intervention for autism spectrum disorders. Furthermore, spironolactone demonstrates substantial anti-androgen properties that might further enhance its appeal in autism, particularly in a definable subset of hyperandrogenic autistic children. One case report is briefly reviewed demonstrating objective clinical improvements in an autistic child after spironolactone administration. Additional research in controlled trials is now needed to further define the risks and benefits of spironolactone use in children with autism.

Abbreviations: DHEA, dehydroepiandrosterone, BDNF, brain derived neurotrophic factor, IL-10, Interleukin-10, TNF-α, tumor necrosis factor alpha, MCP-1, macrophage chemoattractant protein-1, CSF, cerebrospinal fluid, IVIG, intravenous immunoglobulin, ALPS, autoimmune lymphoproliferative syndrome, DHT, dihydrotestosterone, ABC, aberrant behavior checklist

Keywords: Autism, Autism spectrum disorders, Spironolactone, Androgen, Testosterone, Neuroglia, Neuroinflammation, Inflammation, Immune dysregulation, Anti-inflammatory, Anti-androgen

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0306-9877(06)00753-5

doi:10.1016/j.mehy.2006.10.015

Medical Hypotheses
Volume 68, Issue 5 , Pages 979-987, 2007